Characteristics of the study participants included in the intention-to-treat analysis
| Group A# | Group B¶ | Group C+ | Total | |
| Subjects | 1284 | 1299 | 1155 | 3738 |
| Male | 703 (54.75) | 709 (54.58) | 642 (55.58) | 2054 (54.95) |
| Age years | ||||
| 50–55 | 329 (25.62) | 317 (24.40) | 265 (22.94) | 911 (24.37) |
| 56–60 | 332 (25.86) | 344 (26.48) | 295 (25.54) | 971 (25.98) |
| 61–65 | 347 (27.02) | 333 (25.64) | 302 (26.15) | 982 (26.27) |
| 66–69 | 276 (21.50) | 305 (23.48) | 293 (25.37) | 874 (23.38) |
| BMI kg·m−2 | ||||
| <18.5 | 37 (2.88) | 30 (2.31) | 22 (1.90) | 89 (2.38) |
| 18.5– <24 | 523 (40.73) | 543 (41.80) | 472 (40.87) | 1538 (41.14) |
| 24– <28 | 517 (40.26) | 493 (37.95) | 459 (39.74) | 1469 (39.30) |
| ≥28 | 207 (16.12) | 233 (17.94) | 202 (17.49) | 642 (17.17) |
| Completed primary school | 721 (56.20) | 734 (56.59) | 635 (57.89) | 2090 (55.91) |
| Married | 1273 (99.14) | 1289 (99.23) | 1146 (99.22) | 3708 (99.20) |
| Household per capita income >RMB6000 | 678 (52.80) | 655 (50.42) | 607 (52.55) | 1940 (51.90) |
| Ever-smoker | 526 (40.97) | 534 (41.11) | 462 (40.00) | 1522 (40.72) |
| Current alcohol drinker | 403 (31.39) | 398 (30.64) | 342 (29.61) | 1143 (30.58) |
| Pulmonary fibrotic lesions | 22 (1.71) | 14 (1.08)§ | 28 (2.42) | 64 (1.71) |
| Fasting blood glucose >7 mmol·L−1 | 92 (7.17) | 87 (6.70) | 102 (8.83) | 281 (7.52) |
| History of silicosis | 31 (2.41) | 28 (2.16) | 24 (2.08) | 83 (2.22) |
Data are presented as n or n (%). BMI: body mass index. #: intervention Group A completed 8 weeks of once-weekly rifapentine plus isoniazid (both with a maximum dose of 900 mg); ¶: intervention Group B completed 6 weeks of twice-weekly rifapentine plus isoniazid (both with a maximum dose of 600 mg); +: blank controls untreated; §: p-value for Chi-squared test <0.05 between Group B and Group C.